Tempest Therapeutics, Inc. (TPST) Earnings History
Net Loss14 years of earnings data (2012–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Tempest Therapeutics, Inc. (TPST) Earnings Overview
As of June 22, 2026, Tempest Therapeutics, Inc. (TPST) reported trailing twelve-month net income of -$43M, reflecting -322.0% year-over-year growth. The company earned $-3.94 per diluted share over the past four quarters.
Looking at the long-term picture, TPST's historical earnings data spans multiple years. The company achieved its highest annual net income of -$14M in fiscal 2012.
Tempest Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), AGEN ($65M net income, 0.1% margin), AGIO (-$423M net income, -764.0% margin), TPST has comparable earnings metrics. Compare TPST vs IMVT →
TPST Earnings vs Peers
Earnings metrics vs comparable public companies
TPST Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$26M | +37.2% | -$27M | $-6.33 | - | - |
| 2024 | -$42M | -41.9% | -$42M | $-1.50 | - | - |
| 2023 | -$29M | +17.4% | -$29M | $-1.91 | - | - |
| 2022 | -$36M | -26.2% | -$35M | $-3.18 | - | - |
| 2021 | -$28M | -48.0% | -$27M | $-7.80 | - | - |
| 2020 | -$19M | +57.1% | -$19M | $-612.56 | - | - |
| 2019 | -$45M | -63.9% | -$45M | $-48.77 | - | - |
| 2018 | -$27M | +67.8% | -$23M | $-263.65 | - | - |
| 2017 | -$85M | -2.8% | -$20M | $-72406.33 | -28670.5% | -6943.1% |
| 2016 | -$82M | -12.3% | -$81M | $-575.73 | -12597.2% | -12406.1% |
| 2015 | -$73M | -47.9% | -$72M | $-608.25 | -26432.9% | -25992.4% |
| 2014 | -$50M | -70.5% | -$48M | $-491.98 | -508.7% | -492.4% |
| 2013 | -$29M | -115.0% | -$29M | $-288.55 | - | - |
| 2012 | -$14M | - | -$14M | $-2.33 | - | - |
Download Data
Export TPST earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TPST — Frequently Asked Questions
Quick answers to the most common questions about buying TPST stock.
What is TPST earnings per share (EPS)?
TPST trailing twelve-month (TTM) diluted EPS is $-3.94, reflecting -322.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.
What is Tempest Therapeutics, Inc.'s net income?
Tempest Therapeutics, Inc. (TPST) trailing twelve-month net income is $-43M as of 2025. Earnings declined -322.0% year-over-year.
Is TPST profitable?
TPST is not currently profitable on a TTM basis, reporting a net loss of $-43M. Net margin is N/A. Investors should monitor for a return to profitability.
What is TPST's earnings growth rate?
TPST compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.
What are TPST's profit margins?
Tempest Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -203.6%.
Is TPST growing earnings?
TPST earnings are declining — EPS fell -322.0% year-over-year. TTM net income dropped to $-43M. This contrasts with the 5-year CAGR of N/A.
What was TPST's best earnings year?
Tempest Therapeutics, Inc.'s highest annual net income on record is $-14M, achieved in fiscal year 2012. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.
What were TPST's earnings last quarter?
TPST's most recent reported quarter was Q1 2026. Net income was $-28M with diluted EPS of $-2.53. For a full breakdown of all quarters, see the quarterly earnings table on this page.